This product, although approved, is not yet available to purchase via
TheSocialMedwork. However, if you are interested in staying informed
please leave your email address, and we will update you as soon as we
are able to source it and offer it for purchase.
|| Lexicon Pharmaceuticals
|| Carcinoid syndrome
|| Carcinoid syndrome diarrhea
| Approval Status
|| EMA approved (EU); FDA approved (USA)
Other medicines for carcinoid syndrome
If you are interested in other medicines for carcinoid syndrome, please visit our carcinoid syndrome
What is telotristat ethyl?
(telotristat ethyl) is a tryptophan hydroxylase inhibitor indicated for
adults with severe diarrhoea associated with a condition called
carcinoid syndrome 
Carcinoid syndrome is a set of symptoms sometimes seen in people with
carcinoid tumours, whose tumours release excess amounts of the hormone
serotonin, resulting in diarrhea, flushing of the face and cramps 
is used together with other medicines, called somatostatin analogues,
when those medicines are not sufficient on their own to control the
inhibits enzymes needed for the production of serotonin and by reducing
the production of serotonin it relieves the symptoms of the condition 
When will telotristat ethyl be available?
Xermelo (telotristat ethyl) was approved by the FDA on February 28, 2017 
and by the EMA on September 18, 2017 
We have already contacted our sourcing partners and we will offer this
product on our website as soon as we are able to source it for our
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.